# US 2019/0314484 A1 · FUNCTIONAL INFLUENZA VIRUS LIKE PARTICLES (VLPs)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314484 A1
- Document ID: US20190314484A1
- Status: Published application
- Kind: A1
- Application number: 16/210,501
- Filed: 2018-12-05
- Published: 2019-10-17
- Earliest claimed: 2003-07-11
- Assignees: Novavax, Inc.
- Applicants: Novavax, Inc.
- Inventors: Gale SMITH; Rick BRIGHT; Peter M. PUSHKO; Jinyou ZHANG; Kutub MAHMOOD
- Web page: https://patentgrep.com/patent/US20190314484A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/12: Viral antigens
- A61P 31/16: for influenza or rhinoviruses
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/543: {intranasal}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2710/14143: viral genome or elements thereof as genetic vector
- C12N 2760/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16023: Virus like particles [VLP]
- C12N 2760/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16123: Virus like particles [VLP]
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.

## Claims

### Claim at position 1

1-66. (canceled)

### Claim 67

A method of stimulating an immune response in a subject comprising administering an influenza VLP, wherein the VLP comprises influenza proteins, wherein the influenza proteins consist of M1, HA and NA proteins; wherein the M1 protein is derived from a different influenza virus strain than the HA and NA proteins; wherein the influenza proteins are insect-cell expressed, and wherein the M1 protein is from an avian influenza strain.

### Claim 68 (depends on 67)

The method of claim 67, wherein the HA exhibits hemagglutinin activity and/or the NA exhibits neuraminidase activity.

### Claim 69 (depends on 67)

The method of claim 67, wherein the HA and NA proteins are from a seasonal influenza virus.

### Claim 70 (depends on 69)

The method of claim 69, wherein the seasonal influenza virus is a type A influenza virus.

### Claim 71 (depends on 69)

The method of claim 69, wherein the seasonal influenza virus is a type B influenza virus.

### Claim 72 (depends on 67)

The method of claim 67, wherein the influenza VLP comprises avian influenza HA and NA proteins.

### Claim 73 (depends on 72)

The method of claim 72, wherein the avian influenza virus HA and NA proteins are H5 and N1.

### Claim 74 (depends on 72)

The method of claim 72, wherein the avian influenza virus HA and NA proteins are H9 are N2.

### Claim 75 (depends on 67)

The method of claim 67, wherein the influenza VLP is formulated with an adjuvant.

### Claim 76 (depends on 75)

The method of claim 75, wherein the adjuvant comprises paucilamellar nonphospholipid vesicles.

### Claim 77 (depends on 67)

The method of claim 67, wherein the subject is a human.

### Claim 78 (depends on 67)

The method of claim 67, wherein the influenza VLP is administered orally, intradermally, intranasally, intramuscularly, intraperitoneally, intravenously, or subcutaneously.

### Claim 79 (depends on 67)

The method of claim 67 wherein the insect cell is an Sf9 cell.

### Claim 80 (depends on 67)

The method of claim 67 wherein the HA protein is selected from the group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15 and H16.

### Claim 81 (depends on 67)

The method of claim 67 wherein the NA protein is selected from the group consisting of N1, N2, N3, N4, N5, N6, N7, N8 and N9.
